1. Home
  2. LYEL vs DHY Comparison

LYEL vs DHY Comparison

Compare LYEL & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

SELL

Current Price

$13.64

Market Cap

195.8M

Sector

Health Care

ML Signal

SELL

DHY

Credit Suisse High Yield Bond Fund

SELL

Current Price

$16.22

Market Cap

224.2M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
LYEL
DHY
Founded
2018
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
195.8M
224.2M
IPO Year
2021
1998

Fundamental Metrics

Financial Performance
Metric
LYEL
DHY
Price
$13.64
$16.22
Analyst Decision
Buy
Analyst Count
8
0
Target Price
★ $37.63
N/A
AVG Volume (30 Days)
★ 212.6K
48.1K
Earning Date
11-04-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $36,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$7.20
$1.61
52 Week High
$45.00
$17.05

Technical Indicators

Market Signals
Indicator
LYEL
DHY
Relative Strength Index (RSI) 54.63 63.11
Support Level $12.25 $15.90
Resistance Level $14.97 $16.38
Average True Range (ATR) 1.67 0.24
MACD -0.18 -0.38
Stochastic Oscillator 43.74 17.65

Price Performance

Historical Comparison
LYEL
DHY

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

About DHY Credit Suisse High Yield Bond Fund

Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.

Share on Social Networks: